The Global Albumin Market is expected to grow at a rate of 6% by 2026. The development of albumin-based nanoparticles for drug delivery, high demand for albumin in R&D activities & clinical trials, ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including ...

Objective Short-term efficacy of induction therapy with intravenous immunoglobulin (Ig) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) is well established. However, data of ...

Thursday 5th June, 2025 The Health Ministry is in the news for the wrong reasons again. Its decision to resume the use of a stock of immunoglobulin, withdrawn from the government hospitals last year ...

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

He refuted recent media reports that claimed the same immunoglobulin product that caused past controversy is still being administered, stating that such claims are false. Dr. Wijewickrama emphasised ...

Targeted hypermutation of immunoglobulin variable region genes occurs in B cells during an immune response1, and gives rise to families of related mutant antibodies which are then selected for ...

“Godfather” of AI calls out latest models for lying to users Turing Award-winner Yoshua Bengio warns recent models display dangerous characteristics.

Comments - Keheliya to be indicted over import of substandard Immunoglobulin. Clap clap Tuesday, 03 June 2025 08:00 PM . Hope the perpetrators receive they and serve the full sentence without bail.

Otsuka Pharmaceutical Development & Commercialization, Inc.Visionary Study: Phase 3 Trial of Sibeprenlimab in Immunoglobulin A Nephropathy (IgAN). Clinicaltrials.gov.